Back to Search
Start Over
Telik's proteasome program meets preclinical development milestone.
- Source :
- PharmaWatch: Cancer; Oct2008, Vol. 7 Issue 10, p7-7, 1/2p
- Publication Year :
- 2008
-
Abstract
- The article reports on the announcement made by Telik Inc. that its small molecule proteasome inhibitor program has met a preclinical development through an anticancer activity in preclinical models of human leukemia. According to Telik, the inhibitors are orally active, non-peptide, non-boron based which may lead to a drug candidate. Telik vice president of biology James Keck noted that the compounds were achieved through the use of their Trap computational drug discovery technology.
Details
- Language :
- English
- Volume :
- 7
- Issue :
- 10
- Database :
- Complementary Index
- Journal :
- PharmaWatch: Cancer
- Publication Type :
- Report
- Accession number :
- 34707041